AndrewSRhinehartMDFACP,FACE,CDCES

Senior Medical Director at Medtronic Diabetes

Dr. Rhinehart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Andrew Rhinehart is an internal medicine specialist located in Northridge, CA, with significant experience in diabetes mellitus, hypertension, lipid metabolism disorders, abnormal wounds/wound healing, and hyperbaric oxygen therapy. He completed his medical education at the University of Maryland School of Medicine and his residency at East Tennessee State University/Quillen College of Medicine. Dr. Rhinehart serves as Senior Medical Director at Medtronic Diabetes and has held several leadership roles, including Chief Medical Officer at Glytec and President at HealthEd Group, Inc. His research has been published in reputable journals such as Diabetes Technology & Therapeutics, and he has received professional recognition in diabetes management and education.

East Tennessee State University/Quillen College of MedicineResidency, Internal Medicine, 1992 - 1995
University of Maryland School of MedicineClass of 1992
Juniata CollegeB.S., Pre-Medicine Biology, Cum Laude, 1984 - 1988
East Tennessee State University/Quillen College of MedicineChief Residency, Internal Medicine

Certified Diabetes Educator
Board Certified-Advanced Diabetes Management American Association of Diabetes Educators
Certified Diabetese Technology Clinician Diabetes Technology Society
Fellowship American College of Endocrinology, 2015
Diabetes Recognition Program National Committee for Quality Assurance, 2013-2016
Champion for Quality Mountain States Health Alliance Physician, 2012
Fellowship American College of Physicians, 2009
Cup of Kindness Award for Innovation Tri-Cities Business Journal, Health Care Heroes, 2003
Recognized by NCQA Provider Recognition Program for the delivery of quality diabetes care 2002
Join now to see all

PubMed

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes.
Anuj Bhargava, Richard M Bergenstal, Mark L Warren, James R Thrasher, Michael A Dempsey
Diabetes Technology & Therapeutics. 2025-02-06
7 citations
A Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection Technology.
Benyamin Grosman, Anirban Roy, Louis Lintereur, Kamuran Turksoy, Andrea Benedetti
Diabetes Technology & Therapeutics. 2024-03-01
6 citations
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
James R Thrasher, Arcelia Arrieta, Fang Niu, Katherine R Cameron, Toni L Cordero
Diabetes Technology & Therapeutics. 2024-03-01

Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes TechnologiesMay 16th, 2019
Glytec Adds Smart Meter to Growing Network of Connected Solution PartnersJune 6th, 2018
News 8/2/17August 1st, 2017

Member, American Diabetes Association Primary Care Advisory Group 2012 - Present
Member, American Diabetes Association Prevention Committee 2013 - 2014
Chair, American Diabetes Association Primary Care Advisory Group 2013 - 2014
Member, American Diabetes Association Professional Practice Committee 2011 - 2012
Member, Revision Workgroup for National Standards of Diabetes Self Management Education 2011 - 2012